Lentivirus-induced dendritic cells for immunization against high-risk WT1+ acute myeloid leukemia

Human Gene Therapy

Volumn 24, Issue 2, 2013, Pages 220-237

  Sundarasetty, Bala Sai ^a   Singh, Vijay Kumar ^b   Salguero, Gustavo ^a   Geffers, Robert ^c   Rickmann, Mareike ^a   MacKe, Laura ^a   Borchers, Sylvia ^a   Figueiredo, Constanca ^a   Schambach, Axel ^a   Gullberg, Urban ^d   Provasi, Elena ^e   Bonini, Chiara ^e   Ganser, Arnold ^a   Woelfel, Thomas ^b   Stripecke, Renata ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d LUND UNIVERSITY   (Sweden)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 4; INTERLEUKIN 8; LENTIVIRUS VECTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DONOR LYMPHOCYTE INFUSION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INNATE IMMUNITY; MONOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ADOPTIVE TRANSFER; ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL SURVIVAL; DENDRITIC CELLS; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENES, WILMS TUMOR; GENETIC THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-4; LENTIVIRUS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MICE; MONOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RISK FACTORS;

EID: 84874288984     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.128     Document Type: Article

References (41)

1. Bacher, U., Haferlach, C., Schnittger, S., et al. (2009). Interactive diagnostics in the indication to allogeneic SCT in AML. Bone Marrow Transplant 43, 745-56.
2. Betts, M.R., Brenchley, J.M., Price, D.A., et al. (2003). Sensitive and viable identification of antigen-specific CD8 + T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281, 65-78.
3. Biffi, A., Bartolomae, C.C., Cesana, D., et al. (2011). Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 117, 5332-9.
4. Britten, C.M., Meyer, R.G., Kreer, T., et al. (2002). The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J. Immunol. Methods 259, 95-110.
5. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-23.
6. Case S.S., Price, M.A., Jordan, C.T., et al. (1999). Stable transduction of quiescent CD34( + )CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl. Acad. Sci. U.S.A 96, 2988-93.
7. Cavalieri, S., Cazzaniga, S., Geuna, M., et al. (2003). Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102, 497-505.
8. Cilloni, D., Renneville, A., Hermitte, F., et al. (2009). Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J. Clin. Oncol. 27, 5195-201.
9. Gupta, V., Tallman, M.S., and Weisdorf, D.J. (2011). Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 117, 2307-18.
10. Ho, W.Y., Nguyen, H.N., Wolfl, M., et al. (2006). In vitro methods for generating CD8 + T-cell clones for immunotherapy from the naive repertoire. J. Immunol. Methods 310, 40-52.
11. Jedema, I., Van Der Werff, N.M., Barge, R.M., et al. (2004). New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 103, 2677-82.
12. Kalos, M., Levine, B.L., Porter D.L., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73.
13. Keilholz, U., Letsch, A., Busse, A., et al. (2009). A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113, 6541-8.
14. Koya, R.C., Kimura, T., Ribas, A., et al. (2007). Lentiviral vectormediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol. Ther. 15, 971-80.
15. Koya, R.C., Weber, J.S., Kasahara, N., et al. (2004). Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14 + monocytes generates dendritic cells in vitro. Hum. Gene Ther. 15, 733-48.
16. Kuball, J., De Boer, K., Wagner, E., et al. (2011). Pitfalls of vaccinations with WT1-, Proteinase3-and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol. Immunother. 60, 161-71.
17. Maslak, P.G., Dao, T., Krug, L.M., et al. (2010). Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 116, 171-9.
18. Matsue, H., Yao, J., Matsue, K., et al. (2006). Gap junctionmediated intercellular communication between dendritic cells (DCs) is required for effective activation of DCs. J. Immunol. 176, 181-90.
19. Merten, O.W., Charrier, S., Laroudie, N., et al. (2011). Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum. Gene Ther. 22, 343-56.
20. Pincha, M., Sundarasetty, B.S., and Stripecke, R. (2010). Lentiviral vectors for immunization: an inflammatory field. Expert Rev. Vaccines 9, 309-21.
21. Pincha, M., Salguero, G., Wedekind, D., et al. (2011). Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells. Gene Ther. 18, 750-64.
22. Pincha, M., Sundarasetty, B.S., Salguero, G., et al. (2012). Identity, potency, in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapy. Hum. Gene Ther. Methods 23, 38-55.
23. Porter, D.L. (2011). Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Hematology Am. Soc. Hematol. Educ. Program 2011, 292-8.
24. Porter, D.L., Levine, B.L., Kalos, M., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-33.
25. Pospori, C., Xue, S.A., Holler, A., et al. (2011). Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. Blood 117, 6813-24.
26. Rezvani, K., Yong, A.S., Mielke, S., et al. (2008). Leukemiaassociated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111, 236-42.
27. Rezvani, K., Yong, A.S., Mielke, S., et al. (2011). Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 96, 432-40.
28. Rickmann, M., Krauter, J., Stamer, K., et al. (2011). Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann. Hematol. 90, 1047-58.
29. Salguero, G., Sundarasetty, B.S., Borchers, S., et al. (2011). Preconditioning therapy with lentiviral vector-programmed dendritic cells accelerates the homeostatic expansion of antigenreactive human T cells in NOD.Rag1-/-.IL-2rgammac-/-mice. Hum. Gene Ther. 22, 1209-24.
30. Sato, K., Nakaoka, T., Yamashita, N., et al. (2005). TRAILtransduced dendritic cells protect mice from acute graftversus-host disease and leukemia relapse. J. Immunol. 174, 4025-33.
31. Scheibenbogen, C., Letsch, A., Thiel, E., et al. (2002). CD8 Tcell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100, 2132-7.
32. Schlenk, R.F., Dohner, K., Krauter, J., et al. (2008). Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358, 1909-18.
33. Sloand, E.M., Melenhorst, J.J., Tucker, Z.C., et al. (2011). T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 117, 2691-9.
34. Spassov, B.V., Stoimenov, A.S., Balatzenko, G.N., et al. (2011). Wilms' tumor protein and FLT3-internal tandem duplication expression in patients with de novo acute myeloid leukemia. Hematology 16, 37-42.
35. Stripecke, R. (2009). Lentiviral vector-mediated genetic programming of mouse and human dendritic cells. Methods Mol. Biol. 506, 139-58.
36. Sugiyama, H. (2010). WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn. J. Clin. Oncol. 40, 377-87.
37. Svensson, E., Eriksson, H., Gekas, C., et al. (2005). DNA-binding dependent and independent functions of WT1 protein during human hematopoiesis. Exp. Cell Res. 308, 211-21.
38. Van Tendeloo, V.F., Van De Velde, A., Van Driessche, A., et al. (2010). Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl. Acad. Sci. U.S.A. 107, 13824-9.
39. Weber, G., Karbach, J., Kuci, S., et al. (2009). WT1 peptidespecific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia 23, 1634-42.
40. Wolfl, M., Kuball, J., Ho, W.Y., et al. (2007). Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8 + T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110, 201-10.
41. Zilliox, M.J., Parmigiani, G., and Griffin, D.E. (2006). Gene expression patterns in dendritic cells infected with measles virus compared with other pathogens. Proc. Natl. Acad. Sci. U.S.A. 103, 3363-8.